Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Liabilities and Shareholders Equity: 2009-2021

Historic Liabilities and Shareholders Equity for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $247.3 million.

  • Avadel Pharmaceuticals' Liabilities and Shareholders Equity fell 44.81% to $145.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $772.1 million, marking a year-over-year decrease of 32.94%. This contributed to the annual value of $247.3 million for FY2021, which is 20.66% down from last year.
  • According to the latest figures from FY2021, Avadel Pharmaceuticals' Liabilities and Shareholders Equity is $247.3 million, which was down 20.66% from $311.6 million recorded in FY2020.
  • Avadel Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $311.6 million for FY2020, and its period low was $151.4 million during FY2019.
  • In the last 3 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $247.3 million in 2021 and averaged $236.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first declined by 24.86% in 2018, then skyrocketed by 105.79% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $253.3 million in 2017, then fell by 24.86% to $190.3 million in 2018, then dropped by 20.42% to $151.4 million in 2019, then surged by 105.79% to $311.6 million in 2020, then decreased by 20.66% to $247.3 million in 2021.